Infinity Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Infinity Pharmaceuticals

INFI 0.0160

-4.8%

Sep 29 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tuck who wrote (129)	11/19/2006 5:44:16 PM
From: Mike McFarland	Read Replies (1) of 210

The course of treatment for refractory GIST is shorter than myeloma? fwiw, Infinity once listed in a press release Gleevec resistant GIST Herceptin resistant breast cancer Tarceva resistant lung cancer Velcade resistant multiple myeloma I am curious which trials would enroll the fastest. Maybe Perkins said what she said simply because Infinity has a partner in Medimmune, but Kosan does not. Just thinking out loud when what I really need to do is read your last ten posts again.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next